NSCLC: Novel Combination Therapies – Research Path

This path is for exploring research around novel emerging combination therapies for the treatment of NSCLC.

Course Content

ARC-7 Finds Targeting Both PD-1 and TIGIT in NSCLC Is More Efficacious Than Targeting PD-1 Alone – Dec 2022

CheckMate-227 5-Year Data Show Significant Survival Benefit of Combination Immunotherapy for Metastatic NSCLC – Nov 2022

Promising Results Seen With Combination Ramucirumab/Pembrolizumab in Advanced NSCLC – July 2022

Tiragolumab plus atezolizumab showed meaningful improvement progression free survival compared with placebo plus atezolizumab -June 2022

Not Enrolled

Login to Enroll

Free

Course Includes

4 Lessons